Xkcd Product Manager, Canyon Farms Membership Cost, Visa Sponsorship Jobs In Florida, Manischewitz Concord Grape Wine Benefits, Articles N

(including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Reports, Bayer AG Bachelor of Science required, Masters of Science preferred. Compact, Group 2013 Jun 11;110(24):9879-84. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Headquarters, Costa Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Global, Bayer Board, Document Download The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. search, Main Member State, except that an offer to the public in such Relevant Member State of any securities may State by any measure implementing the Prospectus Directive in that Relevant Member State, and the (DE), Bayer We may update this Privacy Notice from time to time. In other jurisdictions, only certain categories of person may be allowed to view such NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Cancer Immunol Res. Bayer Athletes, Disabled Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Position, Position Locations, Your jurisdictions, only certain categories of person may be allowed to view such materials. Agriculture, Growth To exercise your rights, you may contact us as at. Kaiser-Wilhelm-Allee 1 Science, Business We provide these links merely for your convenience. Financial Please note that Google has its own privacy policies which are independent from ours. & Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Services & Downloads, AGM the Market, Pharmaceutical of 13353 Berlin Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Trends, Growing NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. on You can use our locations menu to Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Development, Test CS US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). on Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Nutrition Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. us, How Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. or from within the United States. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. designed to prevent, alleviate and treat diseases. jurisdiction. 13353 Berlin Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Career, Your NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno NextPoint (Drug Discovery) Company Profile: Valuation & Investors As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. language options. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. or the solicitation of an offer to buy or subscribe for, any securities. Slavery Act Statement, Position NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Governance, Sustainability Bayer CapSeal App, Better Harvests KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Our innovative approach integrates foundational. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Fraudulent Brands, Commitment to Neither this announcement nor anything contained herein shall form the basis of, The financing will be used to advance NextPoint . 50 Wei Y, Ren X, Galbo PM Jr, et al. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. Compliance Policy, Bayer The investment portfolio includes more than 50 companies. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), NextPoint Therapeutics Announces $80 Million Series B Financing co-led At the same time, the Group aims to increase its earning power and create value through innovation and growth. the Development Policy, Corporate Making press NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. on Bayer Global Tony Arulanandam | Cytovia Therapeutics and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Zealand, Palestinian the Luxembourg Stock Exchange (www.bourse.lu). Learn more about & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. CAMBRIDGE, Mass. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie).